Topiramate injection - CyDex
Alternative Names: Captisol®-enabled topiramate IV; Captisol®-enabled topiramate injectionLatest Information Update: 08 Mar 2024
Price :
$50 *
At a glance
- Originator CyDex Pharmaceuticals
- Developer CURx Pharmaceuticals
- Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
- Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Epilepsy; Seizures
Most Recent Events
- 07 Mar 2024 Topiranate injection is still in phase-I development in Epilepsy in USA (IM, Injection)
- 07 Mar 2024 Topiranate injection is still in phase-I development in Epilepsy in USA (IV, Injection)
- 07 Mar 2024 Topiranate injection is still in phase-I development in Seizures in USA (IM, Injection)